
Miriam Merad, MD, PhD
- DIRECTOR, PRECISION IMMUNOLOGY INSTITUTE
- PROFESSOR | Oncological Sciences
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Dermatology
Research Topics:
Cancer, Chemokines, Dendritic Cells, Immunological Tolerance, Immunology, Lymphocytes, Macrophage, Microglia, Stem Cells, T Cells, TransplantationMiriam Merad, MD, PhD, is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Dr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on the development of novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, a group of cells that control adaptive immunity. She identified a new subset of dendritic cells, which is now considered a key target of antiviral and antitumor immunity.
Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology, medicine, technology, physics, mathematics and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai, one of the world’s most sophisticated research centers, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses.
Dr. Merad has authored more than 200 primary papers and reviews in high profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease, and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President-elect of the International Union of Immunological Societies (IUIS). In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.
Please visit Dr. Merad's Lab website: http://www.meradlab.org
Multi-Disciplinary Training Area
Immunology [IMM]Education
MD, University of Algiers
Residency, University Paris VII (Interne des hopitaux de Paris)
MS (DEA), University Paris VII
PhD, Stanford University and University Paris VII
Postdoctoral Fellow, Stanford University
-
2014
Endowed Professorship
Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, Sastre-Perona A, Park MD, Tabachnikova A, Dhainaut M, Hamon P, Maier B, Sawai CM, Agulló-Pascual E, Schober M, Brown BD, Reizis B, Marron T, Kenigsberg E, Moussion C, Benaroch P, Aguirre-Ghiso JA, Merad M. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 2021 Jul; 595(7868).
Bogunovic D, Merad M. Children and SARS-CoV-2. Cell host & microbe 2021 07; 29(7).
Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, Mancusi R, Abhyankar H, Casanova-Acebes M, Laface I, Akturk G, Jobson J, Karoulia Z, Martin JC, Grout J, Rafiei A, Lin H, Manz MG, Baccarini A, Poulikakos PI, Brown BD, Gnjatic S, Lujambio A, McClain KL, Picarsic J, Allen CE, Merad M. BRAF-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature medicine 2021 05; 27(5).
Price JG, Idoyaga J, Merad M. Reply to: . Nature immunology 2016; 17: 345-346.
Merad M, Salmon H. Cancer: A dendritic-cell brake on antitumour immunity. Nature 2015; 523: 294-5.
Greter M, Merad M. Regulation of microglia development and homeostasis. Glia 2013; 61: 121-7.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Merad during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Asher, Inc; Dren Bio; Morphic; myeloid therapeutics; nirogy; oncoresponse
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.